Prosoma

Prosoma is a medical company creating digital therapeutics products for cancer patients. We develop a portfolio of digital therapeutics medical software products that cover the entirety of behavioural treatment needs of cancer patients. Our clinically validated platform is set to be prescribed by doctors and therapists in Germany, and it will be reimbursed by the local healthcare system in Q1 2022. We aim to become #1 global digital therapeutics solution for oncology and we have a pathway to get there. Prosoma’s “Software as a Medical Device” platform is a set of stand-alone apps tailored to the different stages of the patient’s journey, which includes: symptoms and treatment support, psycho-social support, and behavioural support. All of these pathways are clinically validated and accessible at any time and anywhere the patient needs it. Our medical self-care applications are designed to deliver therapeutic methods personalised to each patient based on their diagnosis and outcomes. It is the most comprehensive toolset to make patient’s life better. Prosoma is developed by medical experts and patients. We partner with the most renowned organisations for the clinical trials, as well as, large scale commercial partners in the USA and Germany. We are a part of various acceleration programmes such as: Accelerate Cambridge, Incredibles, and the HealthHub at the University of California. Prosoma is being developed and built to meet EU Medical Device Regulations: ISO 13485, ISO 62304, and ISO 27001. We are proud to be funded by a VC fund and Business Angels who support our vision and strategy. In 2020, Prosoma received an NCBiR grant for developing a COVID-19 centred product.